159 related articles for article (PubMed ID: 2724430)
1. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Fair WR; Whitmore WF; Melamed MR
J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
[TBL] [Abstract][Full Text] [Related]
2. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
4. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
6. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
7. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
8. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
9. Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry.
Staiano-Coico L; Huffman J; Wolf R; Pinsky CM; Herr HW; Whitmore WF; Oettgen HF; Darzynkiewicz Z; Melamed MR
J Urol; 1985 May; 133(5):786-8. PubMed ID: 3989917
[TBL] [Abstract][Full Text] [Related]
10. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
[TBL] [Abstract][Full Text] [Related]
12. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
13. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
[TBL] [Abstract][Full Text] [Related]
14. Bladder cancer immunotherapy.
Lamm DL; Thor DE; Stogdill VD; Radwin HM
J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
[TBL] [Abstract][Full Text] [Related]
15. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by serial flow cytometry.
Badalament RA; Gay H; Whitmore WF; Herr HW; Fair WR; Oettgen HF; Melamed MR
Cancer; 1986 Dec; 58(12):2751-7. PubMed ID: 3779622
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Soloway MS; Perry A
J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
Torrence RJ; Kavoussi LR; Catalona WJ; Ratliff TL
J Urol; 1988 May; 139(5):941-4. PubMed ID: 3361668
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer.
Mydlo JH; Usher SM; Camacho F; Freed S
Urology; 1986 Sep; 28(3):173-5. PubMed ID: 3750596
[TBL] [Abstract][Full Text] [Related]
20. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
Catalona WJ; Ratliff TL
Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
[No Abstract] [Full Text] [Related]
[Next] [New Search]
